TOKYO, Japan – October 31, 2025 — Nxera Pharma Co., Ltd. announced that its subsidiary, Nxera Pharma Japan, has received a manufacturing approval partial amendment from Japan’s Ministry of Health, Labour and Welfare (MHLW) for QUVIVIQ® (daridorexant) 25 and 50 mg, adding a new active pharmaceutical ingredient (API) manufacturing site in Asia. This expansion will strengthen supply resilience for insomnia patients in Japan and across the Asia-Pacific (APAC) region while driving cost reductions and profitability improvements aligned with Nxera’s 2030 Vision.
Science Significance
QUVIVIQ® (daridorexant) is a dual orexin receptor antagonist developed to improve sleep onset and maintenance in adults with chronic insomnia. The establishment of a second API manufacturing site ensures consistent quality and availability of this innovative therapy. Nxera’s decision underscores the importance of advanced pharmaceutical process optimization, ensuring quality, stability, and scalability in line with Good Manufacturing Practice (GMP) standards. By localizing API production closer to demand centers, the company reinforces its science-driven manufacturing approach that integrates precision formulation and supply reliability.
Regulatory Significance
The MHLW’s approval represents a key regulatory milestone for Nxera Pharma, validating the company’s cGMP compliance and supply-chain expansion strategy in Asia. This approval supports Nxera’s broader regulatory footprint, complementing ongoing activities in Taiwan, where daridorexant is under review, and South Korea, where it is in Phase 3 trials. These developments collectively demonstrate Nxera’s adherence to regional regulatory harmonization and its alignment with international quality frameworks essential for consistent patient access and product integrity.
Business Significance
Advertisement
The new API site marks a major strategic step toward Nxera’s goal of achieving JPY 50 billion in sales and a profit margin above 30% by 2030. The company anticipates manufacturing cost reductions starting in 2027, contributing significantly through 2028. Nxera’s partnership with Shionogi & Co., Ltd. ensures robust commercial distribution in Japan, where projected sales for QUVIVIQ® are JPY 2.5 billion for FY2026. Additionally, licensing agreements with Holling Bio-Pharma Corp. in Taiwan enhance Nxera’s regional presence, signaling sustained commercial expansion and operational efficiency across the APAC market.
Patients’ Significance
For patients struggling with chronic insomnia, this manufacturing expansion translates to greater accessibility and reliability of QUVIVIQ® therapy. The strengthened production network ensures stable supply and reduced shortages, benefiting those who depend on consistent treatment to manage their sleep disorders. Nxera’s cost reduction measures are also expected to improve affordability, ensuring that high-quality insomnia therapy remains widely available to patients in Japan and emerging Asian markets.
Policy Significance
The approval aligns with regional health policy objectives emphasizing pharmaceutical self-reliance, cost efficiency, and supply chain resilience. By adding an Asian API site, Nxera contributes to localized production and reduced dependency on global logistics, supporting sustainable access to essential medicines. The move also underscores regulatory collaboration between Japanese and Asian health authorities, fostering stronger intra-regional pharmaceutical manufacturing capacity consistent with post-pandemic supply stability goals.
Nxera Pharma’s expansion of QUVIVIQ® manufacturing into Asia represents a strategic and regulatory breakthrough that bridges innovation, cost efficiency, and patient benefit. By establishing dual manufacturing capabilities, the company is securing future demand, enhancing profitability, and advancing its vision of sustainable growth across the APAC region. As Nxera continues to optimize its global operations and drive forward its 2030 profitability roadmap, this initiative reinforces its position as a next-generation bio-pharmaceutical leader committed to quality, accessibility, and growth.
Source: Nxera Pharma Co., Ltd. press release
